Anzeige
Mehr »
Montag, 13.07.2026 - Börsentäglich über 12.000 News
Gold-Kupfer-Knaller 2026?: 483 Gramm Gold pro Tonne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGR3 | ISIN: US8246671098 | Ticker-Symbol: SH00
Siehe auch SHIONOGI & CO LTD
München
13.07.26 | 08:07
7,500 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
SHIONOGI & CO LTD ADR Chart 1 Jahr
5-Tage-Chart
SHIONOGI & CO LTD ADR 5-Tage-Chart

Aktuelle News zur SHIONOGI & CO LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.06.UBS stuft Shionogi-Aktie hoch: Günstige Bewertung und Pipeline als Kaufargumente6
01.06.Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative6
12.05.Shionogi & Co., Ltd. Profit Climbs In Full Year430TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share....
► Artikel lesen
21.04.Shionogi starts phase 2 clinical trial for Pompe Disease6
09.04.Shionogi secures $482m BARDA contract to tackle AMR crisis3
SHIONOGI & CO LTD ADR Aktie jetzt für 0€ handeln
08.04.Shionogi nabs initial $119M award from BARDA to establish US antibiotic plant3
07.04.Shionogi USA: ESCMID Global 2026: Shionogi Presents New Real-World Data Highlighting Clinical Effectiveness of Fetroja/Fetcroja (cefiderocol) in MBL-Producing Enterobacterales Infections441Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase...
► Artikel lesen
03.04.Shionogi: $2.5 Billion Acquisition Of RADICAVA Establishes Rare Disease Platform9
01.04.ViiV Healthcare: Pfizer steigt aus, Shionogi erhöht Anteil27
01.04.Shionogi completes purchase of Pfizer stake in GSK's ViiV Healthcare9
24.03.Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream2
10.02.Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.581BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and...
► Artikel lesen
02.02.Shionogi & Co. GAAP EPS of ¥188.00, revenue of ¥500B8
30.01.Shionogi & Co., Ltd. Reports Rise In Nine Months Profit556TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) reported earnings for its nine months that Increased, from last yearThe company's bottom line came in at JPY158.225 billion, or JPY185.91 per share....
► Artikel lesen
25.01.Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership25
20.01.Pfizer exits GSK majority-owned ViiV Healthcare; Shionogi raises stake24
20.01.Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up4
20.01.Pfizer sells its stake in GSK's ViiV for $1.9B, with Shionogi upping its ante in the HIV-focused company21
20.01.Shionogi stockt Anteil an ViiV Healthcare auf - Pfizer steigt aus29
30.10.25Shionogi Announces Corporate Reorganization Following Japan Tobacco Pharma Merger1.154TOKYO (dpa-AFX) - Shionogi & Co., Ltd. Thursday announced it will implement a corporate reorganization and several personnel reassignments, effective December 1, 2025, in line with the upcoming...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1